chemical

aTAG 2139

6970/5

5 mg

483 USD

6970

6970/5

aTAG 2139

5 mg

Degrader of MTH1 fusion proteins for use within the aTAG system

TAG Degradation Platforms

Small Molecules

98%

782.81

?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications. . Negative control aTAG 2139-NEG (Cat. No. 7575) also available. . Mouse DMPK properties are provided in the supplementary file (see below). . MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.

Degrader of MTH1 fusion proteins for use within the aTAG system

Degrader of MTH1 fusion proteins for use within the aTAG system

6-(6-((4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)pyridin-3-yl)-N-methyl-4-(phenylamino)quinoline-3-carboxamide

C42H38N8O8

C42H38N8O8

2387510-81-6

483 USD

Degrader of MTH1 fusion proteins for use within the aTAG system

CFT 2139

Store at -20░C